Physician profile
Lawrence B Babat
NPI 1619978822
$927,893.78
in general payments reported to CMS, 2019-2025
10 companies · $99K in 2025
The $99K reported for 2025 was more than what 92% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250K · 2020: $102K · 2021: $259K · 2022: $20K · 2023: $96K · 2024: $103K · 2025: $99K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $222K · Consulting Fee: $74K · Food and Beverage: $1,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $222,143.06 |
| Consulting Fee | $74,000.00 |
| Food and Beverage | $1,802.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Republic Spine | $881,947.07 | 2019-2025 | Restore Line Extension, Posterior Cervical, Dark Star Posterior Cervical |
| Orthofix Medical, INC. | $43,820.31 | 2019-2025 | Firebird, Icon, Physio-Stim |
| Nevro Corp. | $804.06 | 2019-2023 | Senza |
| Abbott Laboratories | $400.45 | 2022-2025 | Eterna, Proclaim, Octrode |
| Boston Scientific Corporation | $233.61 | 2023-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Artisan |
| Life Spine, INC. | $231.85 | 2024 | Arx |
| Amgen INC. | $220.84 | 2020-2023 | Evenity |
| Biocomposites INC | $140.96 | 2024 | |
| Spinal Elements, INC. | $94.63 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,110,756.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Babat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.